Nielsen Kirk G. 4/A

What Happened
Kirk G. Nielsen, a director of SpyGlass Pharma, reported the conversion (transaction code C) of a total of 3,145,619 derivative/preferred shares into common stock on February 9, 2026. The filing shows four conversion entries (1,690,230; 548,067; 548,067; 359,255). No cash price or sale proceeds are reported because these were automatic conversions of preferred into common prior to the company's IPO.

Key Details

• Transaction date: February 9, 2026 (conversion entries)
• Transaction type: Conversion of derivative securities (code C) — no price per share reported (automatic one-for-one conversion).
• Total shares converted: 3,145,619 common shares.
• Shares owned after transaction: Not specified in this amended filing.
• Footnote F1: The preferred shares automatically converted one-for-one into common stock before the IPO without additional consideration.
• Footnote F2: Some or all of these shares are held directly by Vensana Capital I, L.P.; Nielsen is identified as a managing director of the general partner and may be deemed to share voting/investment power but disclaims beneficial ownership.
• Amendment: This Form 4 amends a prior Form 4 (filed Feb 10, 2026) to correct the number of shares reported in Table II.

Context

• Conversion (code C) here means preferred stock was turned into common stock as part of the IPO mechanics — not a purchase or a sale. No immediate market-direction signal should be inferred from a mandatory conversion.
• The amendment corrects reported counts; the filing does not show an open-market trade, exercise for cash, or any gift/withholding event.